Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
Authors
Keywords
-
Journal
Journal of Ovarian Research
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-04
DOI
10.1186/s13048-019-0579-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations
- (2018) Jaya Singh et al. BREAST CANCER RESEARCH AND TREATMENT
- Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab.
- (2018) Juliet Elizabeth Wolford et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- The efficacy of trabectedin in treating ovarian cancer
- (2017) Eleonora Teplinsky et al. EXPERT OPINION ON PHARMACOTHERAPY
- Optimizing treatment in recurrent epithelial ovarian cancer
- (2017) Giacomo Corrado et al. Expert Review of Anticancer Therapy
- PARP inhibitors: Clinical utility and possibilities of overcoming resistance
- (2017) Benjamin G. Bitler et al. GYNECOLOGIC ONCOLOGY
- International patterns and trends in ovarian cancer incidence, overall and by histologic subtype
- (2017) S.B. Coburn et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer
- (2017) Amit M. Oza et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
- (2017) Sandro Pignata et al. JOURNAL OF CLINICAL ONCOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- (2017) Robert L Coleman et al. LANCET ONCOLOGY
- Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
- (2017) LE Dockery et al. OncoTargets and Therapy
- The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer
- (2017) Shingo Tayama et al. Oncotarget
- PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
- (2017) Tarra Evans et al. Therapeutic Advances in Medical Oncology
- BRCA mutation in ovarian cancer: testing, implications and treatment considerations
- (2017) Robert T. Neff et al. Therapeutic Advances in Medical Oncology
- Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
- (2016) Susan M. Domchek et al. GYNECOLOGIC ONCOLOGY
- Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) Andreas du Bois et al. LANCET ONCOLOGY
- Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
- (2016) Jonathan A Ledermann et al. LANCET ONCOLOGY
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab in ovarian cancer: A critical review of phase III studies
- (2016) Luigi Rossi et al. Oncotarget
- Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients
- (2015) Vasiliki Michalarea et al. CANCER RESEARCH
- Abstract CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort
- (2015) Ursula A. Matulonis et al. CANCER RESEARCH
- Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
- (2015) S. Kummar et al. CLINICAL CANCER RESEARCH
- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
- (2015) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
- (2015) Carol Aghajanian et al. GYNECOLOGIC ONCOLOGY
- Bevacizumab in newly diagnosed ovarian cancer
- (2015) Joyce F Liu et al. LANCET ONCOLOGY
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
- (2015) Sandro Pignata et al. LANCET ONCOLOGY
- Pathobiology of ovarian carcinomas
- (2015) Mojgan Devouassoux-Shisheboran et al. Chinese Journal of Cancer
- Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis
- (2015) Xinyu Qian et al. PLoS One
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
- (2014) Andreas du Bois et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- The role of the fallopian tube in the origin of ovarian cancer
- (2013) Britt K. Erickson et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options
- (2013) Laurie Elit et al. OncoTargets and Therapy
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
- (2012) L. C. Hanker et al. ANNALS OF ONCOLOGY
- Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis
- (2012) Bradley J. Monk et al. EUROPEAN JOURNAL OF CANCER
- Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer
- (2012) Ilan Bruchim et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic strategies in epithelial ovarian cancer
- (2012) Ayako Kim et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: Its possible clinical significance
- (2012) Yin-Ting Chuang et al. Taiwanese Journal of Obstetrics & Gynecology
- Clinical Trials in Recurrent Ovarian Cancer
- (2011) Michael Friedlander et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP inhibition in BRCA-mutated breast and ovarian cancers
- (2010) Stephen L Chan et al. LANCET
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
- (2010) Gordon JS Rustin et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search